UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
|Articles|February 1, 2008
- Psychiatric Times Vol 25 No 2
- Volume 25
- Issue 2
Between Patients
Author(s)Richard M. Berlin, MD
Poetry of the Times
Advertisement
I sip gunpowder green tea from a cracked clay cup I repaired years ago. I love to drink tea and imagine myself as the cup, glued tight enough to hold the boiling brew patients pour into me each hour. My mind likes to drift to dim sum lunch in Chinatown, where red-bean buns, taro root, and baby bok choy steam in bamboo baskets. When my dragon clock chimes the time, and the next patient clears his throat in the waiting room, I savor one last whiff of far-off mountains and take my final sip, always surprised the tea has turned so bitter, so cold.
Articles in this issue
over 18 years ago
Washington Reportover 18 years ago
The Journey of the Locum Tenensover 18 years ago
Through a Glass, Darkly? A Look at Psychiatry's Futureover 18 years ago
Posttraumatic Stress Disorder in Veteransover 18 years ago
Psychopharmacology in the Decade Aheadover 18 years ago
A Beginning Biology of Beliefs?over 18 years ago
Developing an Effective Treatment Protocolover 18 years ago
Cannabinoids and Painover 18 years ago
Brain Maturation Delayed, Not Deviant, in Kids With ADHDAdvertisement
Related to this article
When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
A psychiatry resident and APA Diversity Leadership Fellow explains how social history, open talk about stigma, and bilingual videos can widen access to care.
Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
Review finds ADHD drugs may ease perimenopause brain fog and improve daily focus, but objective cognition gains remain unclear; larger safety and efficacy studies needed.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
2
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
3
Adjustment Disorder Is Hiding in Plain Sight
4
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
5